National Science Foundation

Amphix Bio specializes in the development of therapeutic materials aimed at advancing regenerative medicine. The company focuses on creating nanofiber materials that replicate the structure and dynamic properties of human tissues. By integrating biological signals into these materials, Amphix Bio effectively guides cells to initiate regenerative processes. This innovative approach enables the development of therapies for repairing various tissues, including bone, cartilage, muscle, cardiovascular tissues, and nervous system components such as the brain and spinal cord. With expertise in materials science, stem cell biology, biomolecular design, engineering, medical physics, and informatics, Amphix Bio seeks to translate its promising preclinical and clinical trial results into viable treatment options.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

LiteraSeed is a digital health company that has created a clinically validated platform aimed at enhancing communication between patients and healthcare providers. This platform is specifically designed to assist low health literate patient populations, which includes individuals who may face language barriers or have difficulty articulating their health concerns. By facilitating accurate and remote self-reporting of symptoms, LiteraSeed's technology seeks to prevent misdiagnoses, adverse health events, and unnecessary emergency room visits. The company's focus on improving access to care is particularly beneficial for public health providers serving diverse communities, ensuring that disadvantaged patients receive the attention and resources they need for effective healthcare management.

Amplified Sciences is a molecular diagnostics company developing a point-of-care platform that enables early detection of debilitating diseases. Its sensor-based and optical reporter systems, combined with machine learning and multi-analyte assays, target cancers and chronic conditions such as pancreatic cancer and kidney disease. The technology supports detection of low-abundance disease markers in urine and saliva, with scalability to cost-effective point-of-care formats. The company leverages ultra-sensitive sensing and composition-of-matter intellectual property licensed from Purdue University to deliver single-molecule level detection. Its portfolio aims to improve patient outcomes by enabling rapid, minimally invasive testing, reducing unnecessary procedures, and expediting diagnosis across oncology and other disease areas. The platform has demonstrated prototype data and is positioned for broad applicability across multiple disease states.

MelliCell is a biotechnology company focused on addressing chronic diseases through innovative tissue engineering technology that targets fat cells. The company’s platform enables the conversion of human stem cells into mature fat cells, facilitating their accelerated growth to sizes that surpass conventional limits. This technology aims to shrink fat cells and improve metabolic health, making it applicable for treating conditions such as obesity, diabetes, aging, oncology, and inflammation. MelliCell’s experienced team is developing oral small molecules that not only decrease fat mass but also reverse disease hallmarks while preserving lean mass. The efficacy of MelliCell’s technology has been recognized through various awards and partnerships with leading biopharmaceutical firms, highlighting its potential to enhance health outcomes and quality of life for individuals worldwide.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

Astria Biosciences, based in Pittsburgh, specializes in developing innovative diagnostic and therapeutic solutions for cerebrovascular diseases. The company focuses on addressing neurosurgical challenges through molecular biology, advanced analytics, and small-molecule inhibitors, aiming to provide non-surgical alternatives for neurovascular conditions where surgery is currently the primary option.

CenSyn develops a portable brain health assessment platform. It comprises a handheld EEG device for rapid neurological evaluation, a mobile app for real-time data viewing, and machine learning algorithms to detect mental status changes. This enables medical professionals to conduct cognitive assessments across various settings.

CerFlux develops advanced cancer modeling technology to enhance understanding and treatment of cancer. Its platform uses innovative ex vivo models to evaluate therapeutic efficacy on patient tumor tissue, enabling oncology professionals to improve patient outcomes through tailored therapy approaches.

Metfora develops an innovative blood test utilizing artificial intelligence to identify patterns in metabolites. This enables early detection of chronic lung disorders, heart diseases, and cancers, enhancing treatment outcomes by facilitating timely diagnoses.

BLOCKsyncop is a company focused on developing innovative clinical monitoring devices aimed at enhancing anesthesiology practices. Its primary product is a non-invasive, real-time tool designed to objectively measure and quantify the effectiveness of neural blocks for pain management. This technology assists anesthesiologists in reducing the occurrence of failed neural blocks, minimizing anesthetic toxicity, and optimizing the analgesic requirements for patients. By providing precise data, BLOCKsyncop aims to improve patient outcomes in pain management and support healthcare professionals in delivering safer and more effective anesthesia care.

CoraVie Medical is an early-stage medical device startup focused on improving blood pressure monitoring for patients with uncontrolled hypertension. Their innovative gadget will be the first to provide actionable insights, enabling timely interventions and cost-effective therapies to prevent organ damage.

CPR Therapeutics is a medical device company focused on developing an advanced automated cardiopulmonary resuscitation (CPR) system. The company's innovative technology integrates multiple technological advancements into a single system designed for easy application under emergency conditions. This multimodal CPR system enhances blood flow and the efficacy of electrical countershock, capabilities that are beyond human performance. By combining chest compressions with artificial ventilation, the system aims to preserve brain function and restore spontaneous circulation and breathing in cardiac arrest patients, thereby improving survival rates significantly.

Claria Medical specializes in developing innovative, minimally invasive surgical tools aimed at enhancing women's healthcare procedures. Their primary focus is improving hysterectomy and myomectomy surgeries by reducing tissue spread risk during laparoscopic procedures. Claria has received notable recognitions such as the 'Safer Technologies Designation' from the FDA and grants from the National Science Foundation and National Institute of Health.

Founded in Baltimore, Maryland in 2018, OncoSTING develops innovative therapies for bladder cancer. The company combines the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists to enhance immune response and improve safety profiles.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Oxalo Therapeutics develops therapies to treat rare kidney diseases and prevent recurrent oxalate-related stones, focusing on primary hyperoxaluria and other oxalate pathologies. It leverages microbiome science, translational research, and early-stage technology to create a gut-derived therapy that safely removes oxalate from the body, reducing stone recurrence and related renal complications.

EzraBio is a biotechnology company focused on enhancing ribosome profiling for researchers across various biological samples. The company specializes in RNA adenylation technology, which facilitates efficient and rapid cDNA library construction. By offering streamlined services that encompass sample preparation and deep sequencing, EzraBio aims to simplify the ribosome profiling process. This innovative approach allows medical professionals to uncover hidden coding potential, analyze translational responses, identify tumor-associated antigens, and advance mRNA therapeutics. Through its cutting-edge solutions, EzraBio supports researchers in their quest to deepen understanding of complex biological mechanisms.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies targeting the root causes of cancer affecting immune evasion and drug resistance. Its focus is on recurrent and drug-resistant cancers, aiming to provide effective treatments for adult and childhood cancers.

Simmbion develops a revolutionary system that manufactures therapies within the human body, acting as a 'living pharmacy'. This innovative approach aims to overcome challenges associated with traditional drug delivery methods such as complex manufacturing processes, repeated injections, and high costs. By creating adaptable, reversible cell therapies resistant to supply chain disruptions, Simmbion strives to provide affordable and equitable healthcare solutions globally.

Iaso Therapeutics is a therapeutics company established in 2018 and located in East Lansing, Michigan. The company specializes in the development of vaccines aimed at improving human health and addressing infectious diseases. Its platform is designed to create vaccines targeting various deadly infections, including smallpox, yellow fever, and tetanus. By focusing on innovative vaccine technologies, Iaso Therapeutics seeks to equip healthcare professionals with effective tools to combat diseases and enhance overall public health.

Lura Health develops a non-invasive continuous health monitoring platform that uses saliva as a diagnostic fluid. The company integrates micro-sensors into orthodontic devices such as retainers, aligners, and brackets to continuously measure saliva analytes and securely transmit data to a smartphone app, enabling users to monitor oral health metrics and potentially support broader chronic disease management. Target markets include heart disease, chronic kidney disease, diabetes, and tooth decay. Founded in 2017, the company is based in Cambridge, Massachusetts.

Amphix Bio specializes in the development of therapeutic materials aimed at advancing regenerative medicine. The company focuses on creating nanofiber materials that replicate the structure and dynamic properties of human tissues. By integrating biological signals into these materials, Amphix Bio effectively guides cells to initiate regenerative processes. This innovative approach enables the development of therapies for repairing various tissues, including bone, cartilage, muscle, cardiovascular tissues, and nervous system components such as the brain and spinal cord. With expertise in materials science, stem cell biology, biomolecular design, engineering, medical physics, and informatics, Amphix Bio seeks to translate its promising preclinical and clinical trial results into viable treatment options.

Visicell Medical develops innovative stem cell tracking tools designed to enhance the safety and efficacy of regenerative therapies. Their biodegradable tools enable real-time tracking of injected stem cells in both clinical and pre-clinical settings, aiming to improve treatment outcomes for patients with incurable diseases.

Cytocybernetics specializes in cellular electrophysiology. They offer a user-friendly plug-and-play dynamic clamp system called Cybercyte and provide comprehensive contract research organization (CRO) services, including FDA-mandated drug safety screening, custom electrophysiology studies, modeling, and analysis.

Nostopharma specializes in treating pathologic bone growth to prevent rare bone diseases. Their nanoparticle drug delivery system aids patients in forming new bone following surgeries, burns, injuries, and other traumas, enabling healthcare providers to enhance clinical outcomes.

InvVax develops innovative vaccines using its proprietary platform. Its flagship product is a universal influenza vaccine designed to provide broad, long-lasting protection against all flu strains.

Isolere Bio, established in 2018, is a healthcare company specializing in biotherapeutic purification. Its core business involves simplifying and optimizing the manufacturing process of monoclonal antibodies and Adeno-Associated Viruses (AAVs) using Tangential Flow Filtration (TFF) technology. This streamlined approach aims to enhance global access to these vital drugs and research tools, while facilitating a seamless transition from laboratory-scale production to industrial-level output.

Oncurie is a biotechnology company focused on developing targeted radionuclide therapy aimed at treating metastatic cancer. Utilizing innovative molecular radionuclide technology, Oncurie seeks to deliver radionuclides selectively to metastatic tissues, thereby enhancing treatment efficacy and improving patient outcomes. The company's goal is to provide healthcare providers with advanced therapeutic options that may lead to a cure for various forms of metastatic cancer, including breast cancer. Through its research and development efforts, Oncurie is committed to transforming cancer treatment and addressing unmet medical needs in oncology.

MBF Therapeutics, Inc. is a veterinary oncology company based in Ambler, Pennsylvania, focused on developing and commercializing innovative therapies for cancer treatment in dogs and cats. The company specializes in targeted immunotherapies and small molecule drugs that effectively disrupt tumor cell metabolism while preserving healthy cells and organs. Its product portfolio includes MBFT-101, a combination therapy for sarcomas and lymphoma, featuring a proprietary polyamine transport inhibitor and a potent inhibitor of ornithine decarboxylase, as well as MBFT-102, an immunotherapy based on the tumor suppressor/cytokine mda-7/IL24, which has shown promise in human cancers. Additionally, MBF Therapeutics employs a proprietary DNA vaccine platform and delivery system to develop immunotherapeutic vaccines aimed at enhancing protective immunity against infectious diseases in companion animals and livestock. The company maintains a strategic partnership with the Lankenau Institute for Medical Research to further advance its research and development initiatives.

Vulcan Biologics, established in 2019 and based in Irvine, California, specializes in biotechnology solutions for modulating microbiomes. Its core platform employs bacteriophages, which selectively target and alter specific gut bacteria without affecting the human host, aiming to achieve stable and persistent changes in the microbiome. This approach is primarily focused on treating gluten-related disorders, including gluten sensitivity and celiac disease.

Astek Diagnostics is a healthcare company that develops precision diagnostic technology aimed at improving the diagnosis and treatment of bacterial infections. The company has created a platform that assists physicians in prescribing the correct antibiotics for patients suffering from bacterial sepsis within one hour. Utilizing a single-use cartridge, Astek Diagnostics' device identifies bacterial infections in urine by measuring the oxygen consumption of bacterial species, significantly reducing the turnaround time for results. This innovative approach not only facilitates timely treatment but also helps combat antibiotic resistance through effective susceptibility testing.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Clairways specializes in smart lung monitoring for pharmaceutical clinical trials. Its wearable device captures key respiratory metrics for individuals with asthma, COPD, CF, or other chronic respiratory diseases.

Felix Biotechnology, Inc. is a San Francisco-based company founded in 2019 that specializes in developing biotherapeutics to combat microbial challenges in human health. The company focuses on creating treatments for antibiotic-resistant strains of bacteria and fungi, aiming to address the urgent need for effective management of infectious diseases. By accelerating the deployment of novel biotherapeutics, Felix Biotechnology seeks to provide healthcare professionals with precise and effective tools to tackle these pressing health issues.

Biochip Labs is a company based in Cleveland, Ohio, founded in 2019. It specializes in providing laboratory testing services focused on blood disorders, particularly sickle cell disease and thalassemia. The company offers a range of proprietary microfluidic biomarker assays, including tests for blood cell adhesion, red blood cell deformability, whole blood rheology, and endothelialized microfluidics. These assays are designed to evaluate the effectiveness of emerging targeted and curative therapies, allowing clinicians to monitor patients' responses to treatment accurately.

xMD Diagnostics, based in Annapolis, Maryland, specializes in the biotechnology sector, focusing on molecular diagnostics tools that enhance research and clinical laboratory practices. Formerly known as Bay Resources Development Group, the company employs advanced high-throughput microdissection technology to aid in cancer diagnosis. Its innovative tools enable the isolation and enrichment of specific cells from biopsy and other specimen samples, facilitating downstream applications such as polymerase chain reaction (PCR), genomic and proteomic analyses, next-generation sequencing (NGS), and various molecular testing methods. This technology supports pathologists, oncologists, and other medical professionals in diagnosing, monitoring, and treating patients with cancer and serious genetic diseases.

Niche Biomedical is a platform and therapy development firm that specializes in innovative treatments for chronic injuries and disorders that have not responded to conventional pharmacological methods. The company has developed the ExaStim, a non-invasive neuromodulation system designated as an FDA Breakthrough Device, aimed at treating spinal cord injuries. Additionally, Niche Biomedical is working on a gastrointestinal therapeutic device designed to alleviate postoperative ileus and restore gastrointestinal motility. This device leverages bioelectronic medicine to address diseases and injuries that are resistant to pharmaceutical therapies. The firm is also capable of creating miniaturized implantable devices with advanced functionalities, allowing for diverse electrode configurations to enhance treatment options through neuromodulation.

SpineX develops and tests neuromodulation technologies for non-invasive devices that aid recovery in individuals with neurological conditions such as strokes, spinal cord injuries, multiple sclerosis, and cerebral palsy. Their focus is on restoring bladder, bowel, respiration, sexual, and sensorimotor functions.

Kodikaz Therapeutic Solutions develops a genomic transfer delivery platform for RNA and DNA delivery vectors, aiming to move beyond conventional cancer therapies toward durable cures through targeted gene transfer. Its Zip-Code technology is a cell-specific delivery system derived from an endogenous human mechanism, designed to avoid the challenges of viral delivery and to be applicable across multiple cell types. The company translates cell-recognition and genomic integration mechanisms identified in human cancers into practical therapies, generating both in vitro and in vivo data in oncology to support the development of cell-targeted gene transfer technologies into curative treatments. Applications include cancers such as pancreatic cancer, multiple myeloma, and colorectal cancer, and the platform supports collaborations to help clients develop cell-specific gene transfer approaches.

Frontier Bio Corporation is a biotechnology company based in Oakland, California, focused on developing and manufacturing advanced bioprinting technologies. Founded in 2018, the company specializes in creating lab-grown human tissues as an ethical alternative to animal studies. Its flagship product, the FLUX-1, is a 3D bioprinter that integrates conventional bioprinting methods with electro-hydrodynamic printing capabilities. This device enables the bioprinting of complex tissues such as skin, cartilage, and bone, and allows for applications in drug toxicity testing, tissue implants, drug screening, disease modeling, and prosthetics. By providing a means to produce human tissues with complete cell survivability, Frontier Bio aims to enhance the healthcare industry's ability to replace animal testing and address the organ transplant waitlist.

TheraCea Pharma is a biotechnology company specializing in precision medicine for neurological disorders. Based in Tucson, Arizona, it develops and licenses radiochemistry technology enabling high-efficiency fluorine-18 radiolabeling of biomolecules for clinical and research applications.

ZelosDx is a company focused on developing neurodiagnostic technologies, specifically blood testing products aimed at advancing research in brain health and disease. It offers proprietary technology that allows research collaborators to license and adapt blood testing kits and automated laboratory equipment. Additionally, the company provides pharmaceutical partners with biomarker technology essential for drug discovery tools. By delivering critical data for diagnosis, monitoring, and assessing therapeutic responses, ZelosDx supports researchers and pharmaceutical companies in making significant breakthroughs in understanding and treating brain-related conditions.

Ancilia Biosciences is a biotechnology company focused on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components of the gut microbiome. By concentrating on enhancing healthy gut bacteria and their predatory phages, Ancilia develops therapeutic strains that can effectively combat chronic diseases in the fields of immunology and oncology. Additionally, the company is pioneering a new class of live biotherapeutics that allow for the precise targeting of phages or viruses known to induce lysis, thereby advancing treatment options in microbiome-related health conditions.

LumenAstra, established in 2020 and headquartered in Longmont, Colorado, specializes in the development of non-invasive, wearable deep-tissue temperature sensors. These devices are designed to accurately measure internal temperatures from external locations, serving diverse applications such as cancer hyperthermia therapy, hypothermia for aortic dissection repair, brain temperature monitoring for newborns, and heat stress monitoring in high-risk environments like military operations or hazardous workplaces. The company's innovative sensor technology enables medical professionals to better protect patients from potential harm caused by extreme temperatures.

Founded in 2018, Paramita Therapeutics is a biotechnology company based in San Diego, California. It specializes in developing new therapeutics for cancer and infectious diseases.

ALSUS MEDICAL offers treatment for urinary stream problems that may be weak or stop and start. In some cases, it can lead to infection, bladder stones, and reduced kidney function. They offer treatments that include medication that relaxes or shrinks the prostate, surgery, and minimally invasive surgery.

LiteraSeed is a digital health company that has created a clinically validated platform aimed at enhancing communication between patients and healthcare providers. This platform is specifically designed to assist low health literate patient populations, which includes individuals who may face language barriers or have difficulty articulating their health concerns. By facilitating accurate and remote self-reporting of symptoms, LiteraSeed's technology seeks to prevent misdiagnoses, adverse health events, and unnecessary emergency room visits. The company's focus on improving access to care is particularly beneficial for public health providers serving diverse communities, ensuring that disadvantaged patients receive the attention and resources they need for effective healthcare management.

Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative therapies for distressed neurological conditions and associated symptoms, including pruritus resulting from liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which enhances drug delivery by avoiding first-pass metabolism and significantly reducing glucuronide metabolites excreted by the kidneys. This technology aims to provide effective relief from various conditions, such as insomnia, anxiety, depression, and skin excoriation, thus offering improved efficacy and safety for patients. With a strong management team, an experienced advisory board, and a dedicated group of scientists and clinicians, Avior Bio is well-positioned to advance its mission of delivering high-value therapeutic solutions.

Verantos is the market leader in high-validity real-world evidence for life sciences. By incorporating robust clinical narrative data, artificial intelligence technology, and measured validity, Verantos is the first company to generate research-grade evidence at scale across all therapeutic areas. The Verantos Evidence Platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for market access, HEOR, medical affairs, and regulatory use.

Gate Scientific makes products that enable great research and improve healthcare decisions by bringing to market intuitive solutions that simplify complex problems. By bringing to market intuitive solutions that simplify complex problems, they allow for the latest technologies to benefit more people.

SpheroFill is a drug delivery platform that specializes in creating innovative injectable tissue fillers, specifically designed to address age-related atrophy in the larynx. Utilizing a unique combination of solid, hollow, and porous-wall hollow glass microspheres along with biocompatible and bioactive matrices, SpheroFill enhances drug delivery for healthcare professionals. Its technology enables improved patient compliance by reducing dosing frequency and allows for oral formulations that current technologies cannot achieve. By focusing on the protection, delivery, and controlled release of active pharmaceutical ingredients, SpheroFill represents a significant advancement in the field of drug administration.

Founded in 2019, Precision Theranostics is a biotechnology company headquartered in Baltimore, Maryland. It specializes in developing prognosis-based intervention strategies for the early detection and treatment of fatal diseases, focusing on respiratory diseases and age-related disorders.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Amberstone Biosciences is a biotechnology company focused on discovering novel immunotherapies aimed at addressing challenging medical targets that traditional methods struggle to tackle. The company utilizes its proprietary microfluidics-powered AmberFlow drug-discovery platform, which allows for the analysis of single-cell function within a customizable microenvironment. This innovative approach, combined with the expertise of its team in immuno-oncology and single-cell assay biology, positions Amberstone to develop transformative therapeutic antibodies that cater to patients with unmet medical needs. Through creative partnerships and advanced technologies, Amberstone Biosciences seeks to overcome conventional limitations in therapeutic development, ultimately enhancing patient care and outcomes.

Founded in 2016, Cobio Diagnostics is a biotechnology company based in Golden, Colorado. It specializes in developing diagnostics for bacterial identification and phenotypic antibiotic resistance testing using a phage-based immunoassay. This enables healthcare providers to make quicker and more informed decisions about antibiotic use.

BondTrue is a medical device company working to enhance surgical precision by automating incisions and closures. Its device automates the process of making incisions and closing wounds, enabling rapid, accurate approximation and repair of surgical sites with clean, consistent incisions and precise suturing. The company is advancing its patented technology through research and development funded by a Phase II Maryland Industrial Partnerships grant from the Maryland Technology Enterprise Institute at the University of Maryland. The grant supports ongoing refinement of prototype designs and testing in collaboration with university partners to move the device toward clinical use.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

GRI Bio is a development-stage biotechnology company focused on discovering and developing therapies that modulate Natural Killer T (NKT) cell activity to treat inflammatory, autoimmune, and fibrotic diseases, including liver disease. Based in La Jolla, California, the company develops cell- and molecule-based approaches to regulate NKT cell function and restore immune homeostasis, with programs such as GRI-0621, an oral agent that inhibits type 1 NKT cell activity, and GRI-0803, a novel oral agonist targeting type 2 NKT cells.

iReprogram is a cell regeneration laboratory based in Ann Arbor, Michigan, established in 2017. The company focuses on advancing personalized medicine through innovative cell reprogramming technology. By utilizing a high-fidelity prototype computational tool, iReprogram generates transcription factor recipes that facilitate cellular trans-differentiation, particularly for cancer treatment. This technology aims to enhance the effectiveness of cancer therapies, ultimately allowing patients to benefit from more tailored and effective treatment options.

Progenitor MDX is a biotechnology company focused on developing advanced cellular immunotherapy technologies and innovative solutions for managing COVID-19 infections. The company offers a comprehensive approach that includes testing and actionable infection management plans, aimed at providing reassurance to communities. In addition to its COVID-19 management solutions, Progenitor MDX specializes in cellular reprogramming, utilizing a streamlined method that incorporates all Yamanaka factors into a single vector. This technology enables the creation of allogeneic off-the-shelf CAR constructs from various cell sources, facilitating the efficient insertion of multiple genetic elements. By enhancing the industrial workflows for producing engineered cell therapies, Progenitor MDX plays a critical role in advancing immune-oncology and the development of new therapeutic options.

Akanocure Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative anti-cancer therapies aimed at treating various forms of cancer, particularly those that have metastasized. Recognizing that metastasis is responsible for the majority of cancer-related deaths, Akanocure focuses on creating novel small molecules that can block metastatic processes. The company's approach emphasizes the synthesis and development of bio-targeted chemotherapeutic agents derived from natural resources, which not only target cancer cells more effectively but also address the side effects associated with conventional chemotherapy. By leveraging the expertise of its team throughout the drug discovery and development process, Akanocure aims to enhance treatment outcomes and improve the quality of life for cancer patients.

BioAesthetics develops tissue-engineered nipple-areolar complex grafts to support breast reconstruction after mastectomy. The graft is designed as a scaffold for the patient's own cells to populate and regenerate the nipple and areola during reconstruction, aiming to improve cosmetic and reconstructive outcomes. The company originated as a Tulane University spin-out and was founded in 2015.

Vaxess Technologies is a biotechnology company focused on silk biomaterial platforms for vaccine and therapeutic delivery. It develops the MIMIX microneedle patch for transdermal, sustained-release delivery of vaccines and therapies, designed to improve stability and ease of use, including formulations that do not require cold chain storage. The MATRIX formulation and drying platform supports thermostable vaccine, therapeutic, and diagnostic products. The company aims to enable long-term immune responses and easier distribution, including in low-resource settings. Its technology supports oncology and infectious disease applications, including therapies that promote durable anti-tumor immunity and improved treatment outcomes. Founded in 2011 and based in Boston, the company positions its platforms to enable stable, targeted delivery and potentially reduce treatment burden for patients.

BiomeSense develops an integrated hardware, software, and data platform to scale microbiome data collection and analysis for clinical research. The company integrates at-home monitoring of the gut microbiome through its GutLab smart-bathroom system with the MetaBiome time-series analytics platform to connect microbiome changes with clinical outcomes in real time. Its platform supports large-scale, densely longitudinal datasets to discover, validate, and commercialize microbiome biomarkers, enabling clinicians to apply microbiome insights to improve human health. Founded in 2018 and based in Chicago, BiomeSense seeks to advance precision medicine by providing end-to-end microbiome measurement and analytics.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies targeting the root causes of cancer affecting immune evasion and drug resistance. Its focus is on recurrent and drug-resistant cancers, aiming to provide effective treatments for adult and childhood cancers.

BondTrue is a medical device company working to enhance surgical precision by automating incisions and closures. Its device automates the process of making incisions and closing wounds, enabling rapid, accurate approximation and repair of surgical sites with clean, consistent incisions and precise suturing. The company is advancing its patented technology through research and development funded by a Phase II Maryland Industrial Partnerships grant from the Maryland Technology Enterprise Institute at the University of Maryland. The grant supports ongoing refinement of prototype designs and testing in collaboration with university partners to move the device toward clinical use.

Ionica Sciences, Inc. is a diagnostic company based in Ithaca, New York, founded in 2013. It specializes in developing a spectroscopy-based diagnostic platform that employs surface enhanced Raman scattering (SERS) technology. This innovative approach is designed to diagnose a range of diseases, including vector-borne, sexually transmitted, and neurological conditions. Ionica Sciences focuses on creating in-vitro diagnostic assay tests, particularly for Lyme disease and other infectious diseases, allowing medical professionals to detect biologically relevant targets such as pathogens and hormones. By providing accurate and rapid diagnostic solutions, the company aims to enhance clinical decision-making, reduce unnecessary antibiotic usage, and lower healthcare costs associated with misdiagnoses.

Claria Medical specializes in developing innovative, minimally invasive surgical tools aimed at enhancing women's healthcare procedures. Their primary focus is improving hysterectomy and myomectomy surgeries by reducing tissue spread risk during laparoscopic procedures. Claria has received notable recognitions such as the 'Safer Technologies Designation' from the FDA and grants from the National Science Foundation and National Institute of Health.

FloBio is a Philadelphia-based company founded in 2017 that specializes in point-of-care diagnostics for assessing bleeding risk through real-time blood analysis. The company has developed an innovative fluidic-based diagnostic platform that leverages microfluidic technology to measure blood clotting function under physiologic conditions. This platform delivers rapid and actionable measurements, allowing clinicians to make informed decisions and personalize patient management during critical moments. By focusing on enhancing the accuracy and immediacy of blood analysis, FloBio aims to improve outcomes in medical situations where bleeding risk is a significant concern.

Plexision develops cellular biomarkers and personalized diagnostic tests for immunological disorders and solid organ transplantation. Its Pleximmune blood test predicts transplant rejection by measuring antigen-specific white blood cells, supported by patent-pending technology. The company operates a CLIA-certified central laboratory in Pittsburgh providing testing services for transplant recipients and drug developers. Its platform enables assessment of disease risk, prediction of drug efficacy for individual patients, and guidance on dosing for novel immunological therapies, with capabilities including rapid six-hour panels for conditions such as CMV infection and transplant rejection, and a focus on pediatric liver and intestine transplant patients.

Jupiter Therapeutics is a biotechnology company specializing in the development of cell-membrane-based therapeutics. It employs cell engineering techniques to create customized vesicles aimed at advancing immuno-oncology and gene therapy. By leveraging a synthetic biology approach, Jupiter Therapeutics facilitates the rapid design and synthesis of a diverse pipeline of therapeutic assets that address critical areas such as cancer and autoimmunity. The company allows medical researchers to utilize insights from cell-membrane studies to enhance the effectiveness of CAR T-cells and bi-specific antibodies, thereby contributing to innovative treatments in the biotherapeutics field.

Forcast Orthopedics is a medical technology company focused on enhancing patient outcomes following joint replacement surgery through innovative treatment methods for periprosthetic joint infections. The company has developed a proprietary automated platform that delivers targeted antibiotic therapy, modernizing the approach to infection management. By utilizing this advanced system, Forcast Orthopedics aims to provide superior patient care while also lowering costs and reducing the morbidity associated with traditional treatment methods. Through these efforts, the company seeks to significantly improve the recovery process for patients experiencing infections after joint replacement procedures.

Dascena, Inc. is a healthcare technology company based in Oakland, California, that specializes in developing machine learning algorithms aimed at enhancing disease detection and improving patient care outcomes. Established in 2018, Dascena's flagship product, AlgoDiagnostics, autonomously processes electronic health record data to facilitate early intervention for conditions such as acute decompensation, sepsis, and acute kidney injury. The company focuses on addressing unmet healthcare needs through its innovative solutions in clinical decision support, point-of-care diagnostics, and biopharma companion diagnostics. By leveraging intensive clinical research, Dascena aims to enable clinical practitioners to make timely and accurate interventions, ultimately saving lives and enhancing the delivery of care.

Inherent Biosciences is a molecular diagnostics company focused on transforming the traditional trial and error approach in medicine. The company leverages its innovative epigenetic medicine platform to address various health challenges by identifying gene dysregulation and its associated pathways. By translating biological insights into actionable information, Inherent Biosciences aims to enhance treatment strategies for conditions such as pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. This approach not only guides healthcare professionals in managing complex diseases but also seeks to provide personalized insights that empower patients in their health journeys.

Lura Health develops a non-invasive continuous health monitoring platform that uses saliva as a diagnostic fluid. The company integrates micro-sensors into orthodontic devices such as retainers, aligners, and brackets to continuously measure saliva analytes and securely transmit data to a smartphone app, enabling users to monitor oral health metrics and potentially support broader chronic disease management. Target markets include heart disease, chronic kidney disease, diabetes, and tooth decay. Founded in 2017, the company is based in Cambridge, Massachusetts.

Founded in 2010, VaxForm specializes in vaccine formulation development services. It supports clients from project definition to implementation, focusing on bacterial or viral antigen formulations, vaccine combinations, and live attenuated vaccines. The company also assists in regulatory compliance, patent preparation, and scientific publication writing.

Founded in 2018, Rizlab Health specializes in developing compact blood diagnostic devices. Their flagship product is CytoTracker, a pocket-sized, wireless analyzer powered by artificial intelligence, designed to deliver rapid and affordable white blood cell count analysis.

Radiologics specializes in clinical research and medical imaging services, offering comprehensive software solutions designed specifically for clinical trials. The company’s platform facilitates image data management, streamlining processes such as file transfer, verification, and integration with clinical data. Additionally, it automates image processing routines and enhances connectivity, thereby assisting healthcare professionals in conducting clinical research and improving diagnostic accuracy. Radiologics’ focus on innovation in medical imaging supports advancements in clinical trials and research methodologies.

Prime Labs is a technology company that offers cloud-based SaaS platforms for mass spectrometry data processing, analysis, reporting, and visualization in the field of medical drug discovery. Its software enables scientists to conduct experiments more efficiently, accurately, and comprehensively, streamlining workflows and reducing time spent on typically tedious processes. The platform is user-friendly and requires minimal training or installation, making it accessible to a wide range of users.

Vitanova Biomedical, Inc. is an early-stage biotechnology company based in Kerrville, Texas, focused on developing innovative cancer therapies. Founded in 2015 by Matt Gdovin and Greg Espenhover, the company specializes in Light-Activated Intracellular Acidosis (LAIA), a technique that employs energy-based methods to induce cancer-specific acidosis using specific wavelengths of light and targeted nanoparticles. This approach aims to provide cost-effective and effective treatment options for cancer patients while minimizing side effects, thereby enhancing the quality of care for both patients and healthcare professionals. Vitanova Biomedical's commitment lies in delivering transformative solutions in cancer therapy.

Caza Health is a biotech company specializing in the microbiome, immunology, and oncology. The company was founded in 2019 and is headquartered in Earlysville, Virginia.

Sumaq Life is a technology company specializing in AI-driven healthcare solutions. It focuses on identifying cancer patients eligible for genomic testing by integrating with electronic medical records. The company then employs gene regulatory modeling to develop personalized treatment plans, targeting therapies with a higher likelihood of success across various aggressive cancer types, including metastatic melanoma, osteosarcoma, breast, pancreatic, lung, and colorectal cancer.

Coagulo Medical Technologies develops portable precision-medicine platforms for managing coagulation disorders. Its systems detect, identify, and quantify the effects of anticoagulants in whole blood, providing actionable results to healthcare providers.

Biocogniv develops AI-powered diagnostic tools for hospitals, delivering real-time clinical intelligence by integrating with electronic health records. Its platform analyzes standard blood tests and other data to screen patients for COVID-19 and to predict sepsis-related in-hospital mortality and ICU admission at emergency department presentations, enabling non-invasive, data-driven decision making. The solution plugs into existing EHR workflows to improve quality, lower costs, and expand access to care. The company was founded in 2019 and is based in Burlington, Vermont.

Proteios Technology develops products and services to support the discovery and scalable manufacturing of biopharmaceuticals. It offers protein purification kits, including gravity-based and spin kits, enabling safe and efficient purification with reduced environmental impact and lower costs. Founded in 2015 and headquartered in Issaquah, Washington.

Oscillo Biosciences is a company focused on developing innovative pharmacological treatments for Alzheimer's disease and related disorders. The firm combines a prescription medical device with digital therapeutic solutions aimed at restoring healthy brain function in individuals suffering from mild cognitive impairment and Alzheimer's disease. Their approach is rooted in the understanding that disruptions in brain rhythms affect memory and cognition in these patients. Additionally, Oscillo Biosciences creates human-centered technologies that rehabilitate patients with language, cognitive, and motor impairments by simulating the brain's synchronization to sounds and coordinating rhythmic behaviors like speech and movement. Through real-time perceptual analysis of music and various applications, their therapies offer a comprehensive method to enhance cognitive function and improve the quality of life for affected individuals.

Chosen Diagnostics is a developer of innovative biomarker diagnostic kits designed to enhance healthcare delivery for neonates. The company's primary focus is on diagnosing a prevalent and life-threatening bowel disease in preterm infants. Its diagnostic kit provides more accurate results compared to existing options, facilitating earlier medical intervention. By enabling healthcare professionals to detect critical conditions sooner, Chosen Diagnostics aims to improve treatment outcomes for thousands of low birth weight preterm infants, ultimately contributing to better health and survival rates in this vulnerable population.

Rochal Industries is a research-based company specializing in the development and manufacture of biomaterials for the wound care and eye care industries. Founded in 2014 and headquartered in San Antonio, Texas, the company produces antimicrobial materials designed to reduce opportunistic pathogens and biofilms, as well as cell-compatible substrates. Rochal Industries focuses on creating transformative products that aid in wound re-epithelialization and closure, necrotic tissue debridement, and transdermal drug delivery, guiding these products through concept development to preclinical and clinical stages while adhering to quality and regulatory standards.

Inso Biosciences is an early-stage biotechnology company that develops microfluidic hardware platforms for genomic sample handling. The company's patented microfluidic technology enables high-efficiency processing of cellular material and the separation and isolation of cellular components, supporting genomic analysis and DNA sequencing workflows. Its platform aims to improve long-read DNA extraction, multiomic sample processing, and pathogen surveillance, enabling healthcare and biotech organizations to perform biological sample preparation with greater efficiency and accuracy.

AxonDx is a biotechnology company specializing in the detection of circulating tumor cells (CTCs) in blood samples, which serve as critical indicators of the presence of solid tumors and potential metastases. The company has developed the nCYTE™ technology, a device that rapidly scans un-enriched blood samples, identifying all classes of CTCs within minutes. This innovative approach not only enhances the speed and accuracy of CTC detection but also provides morphological and molecular characterization of the identified cells. By enabling earlier self-diagnosis of cancer and facilitating personalized medical treatment, AxonDx aims to transform cancer management. The company operates a "razor and blade" business model, selling nCYTE™ instruments and associated diagnostic kits for use in clinical settings, making advanced cancer detection accessible and cost-effective at the point of care.

Bioz is a cloud-based, AI-driven search and data-mining platform for life sciences that analyzes peer-reviewed literature, including full text and materials and methods sections, to identify reagents, instruments, equipment, and consumables. It provides relevancy-ranked results, research-relevant correlations, product ratings, and collaboration optimization, helping scientists quickly find, compare, and select the right products. By structuring data from the articles, Bioz accelerates experimentation and speeds drug discovery for researchers in academia and biopharma. Founded in 2013 and based in Palo Alto, Bioz aims to streamline procurement and enable faster scientific progress by turning complex literature into actionable product insights.

Opticyte, Inc. is a medical device company based in Seattle, Washington, specializing in the development of advanced algorithms and optical spectroscopy technology to monitor cellular oxygen levels. Founded in 2016 as a spinoff from the University of Washington, the company is focused on creating its first product, the Cell O2 Monitor, which aims to reduce the risk of organ failure. This innovative noninvasive oximeter measures oxygen levels within cells, enabling early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By providing clinicians with essential data, Opticyte's technology facilitates timely treatment decisions that can prevent multiple organ failure and improve patient outcomes. The company comprises teams with extensive experience in engineering, regulatory affairs, and communications, all dedicated to advancing medical device innovation.

Akanocure Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative anti-cancer therapies aimed at treating various forms of cancer, particularly those that have metastasized. Recognizing that metastasis is responsible for the majority of cancer-related deaths, Akanocure focuses on creating novel small molecules that can block metastatic processes. The company's approach emphasizes the synthesis and development of bio-targeted chemotherapeutic agents derived from natural resources, which not only target cancer cells more effectively but also address the side effects associated with conventional chemotherapy. By leveraging the expertise of its team throughout the drug discovery and development process, Akanocure aims to enhance treatment outcomes and improve the quality of life for cancer patients.

BioAmp Diagnostics, Inc. is a biotechnology company based in Berkeley, California, established in 2017. The company focuses on developing innovative diagnostic tools aimed at addressing the growing issue of antibiotic resistance. Through its patented platform amplification technology, BioAmp creates precision diagnostics that provide actionable results for medical personnel. These tests enable physicians to make informed decisions and prescribe the appropriate antibiotics for patients from the outset, thereby improving treatment outcomes and enhancing patient care. By empowering healthcare providers with critical information, BioAmp aims to facilitate the effective management of infections and contribute to the global fight against antibiotic resistance.

Viora Health is a health and wellness company focused on advancing health equity among diverse populations. It develops tech-enabled, human-centered programs that utilize social and behavioral engagement to enhance the capacity, satisfaction, outcomes, and revenue for healthcare providers. Viora Health's offerings are designed to improve adherence to diabetes prevention and support patients through online tools that track data and report progress to diabetes prevention programs, facilitating compliance with insurance requirements. Funded by reputable organizations such as the American Heart Association, the National Institutes of Health, Johnson and Johnson, and the National Science Foundation, Viora Health's initiatives have shown significant success, achieving a 75% satisfaction score and double retention rates, while also leading to improved patient outcomes such as reduced stress, increased social support, and better access to food.

Capienda Biotech is a biotechnology company focused on enhancing the drug discovery process by developing an innovative bioanalytical platform. This platform combines advanced instrumentation with assay chemistry, allowing for higher quality small molecule designs and significantly improving the efficacy of drug development. By providing crucial data that addresses a critical bottleneck in the industry, Capienda helps reduce the time and cost associated with bringing new medicines to market. Its high-throughput kinetics system offers a throughput 48 times greater than traditional methods, streamlining the process without requiring specialist scientists. The company generates recurring revenue through the sale of its laboratory instrument systems and assay chemicals, positioning itself as a key player in the biotechnology sector.

Niche Biomedical is a platform and therapy development firm that specializes in innovative treatments for chronic injuries and disorders that have not responded to conventional pharmacological methods. The company has developed the ExaStim, a non-invasive neuromodulation system designated as an FDA Breakthrough Device, aimed at treating spinal cord injuries. Additionally, Niche Biomedical is working on a gastrointestinal therapeutic device designed to alleviate postoperative ileus and restore gastrointestinal motility. This device leverages bioelectronic medicine to address diseases and injuries that are resistant to pharmaceutical therapies. The firm is also capable of creating miniaturized implantable devices with advanced functionalities, allowing for diverse electrode configurations to enhance treatment options through neuromodulation.

Inso Biosciences is an early-stage biotechnology company that develops microfluidic hardware platforms for genomic sample handling. The company's patented microfluidic technology enables high-efficiency processing of cellular material and the separation and isolation of cellular components, supporting genomic analysis and DNA sequencing workflows. Its platform aims to improve long-read DNA extraction, multiomic sample processing, and pathogen surveillance, enabling healthcare and biotech organizations to perform biological sample preparation with greater efficiency and accuracy.

VivoZ Biolabs specializes in developing cell culture platforms that replicate the complex 3D tumor microenvironment. The company's flagship technology is a patented layered microfluidic tissue assay, which serves as an ex vivo platform for drug screening, diagnosis, and personalized cancer treatment. This innovative microfluidic array mimics the dynamic conditions of tumor tissue, allowing for mid-to-high throughput maintenance of micro-tumor growth and functions. This capability enables healthcare professionals to predict and select candidate compounds more effectively during the drug discovery process.